Osteopontin: an unhealthy sleep remedy for ALL 
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During the last 2 decades, there has been substantial progress in identifying key cellular and molecular players in crosstalk between normal and malignant hematopoietic cells and the marrow microenvironment. 4 At least 2 hematopoietic stem cell (HSC) bone marrow niches have been described: one endosteal and one perivascular (see figure) . How can we stop leukemia cells from parasitizing in these niches and give them a taste of their own medicine? CXCR4, a chemokine receptor that tethers hematopoietic cells to CXCL12-secreting stromal cells, is the first therapeutic target for disrupting crosstalk between leukemia cells and the marrow microenvironment. 7 Many clinical trials use CXCR4 antagonists (eg, plerixafor/AMD3100) for "chemosensitization" when given in combination with cytotoxic agents. These studies are either ongoing or are recently finished, and a first trial in acute myeloid leukemia has reported encouraging results. 8 Targeting OPN in ALL, as introduced in this study, 1 follows a similar concept: OPN neutralization releases ALL cells from their dormant state in the endosteal niches and makes them better accessible and receptive toward cytotoxic drugs that target cycling cells. As such, this study is in line with an ongoing important paradigm shift in cancer therapy, moving from cancer cells as the primary target of therapy toward new treatments that also interfere with protective tumor-microenvironment interactions. 9 It is also tempting to think about analogies between OPN and "The Sleeping Beauty": ALL cells are doomed to sleep in endosteal niches by OPN, but once this curse is lifted, life in the marrow awakens. The encouraging data about OPN neutralization in ALL in this study 1 stir hope that, unlike in "The Sleeping Beauty", it will take a much shorter time than 100 years until the reversion of leukemia cell dormancy in ALL can be clinically tested.
Conflict-of-interest disclosure: The author declares no competing financial interests. n JMML patient-derived iPSCs induce new hypotheses to be the recipient of intense investigation because its only curative therapy is allogeneic hematopoietic stem cell (HSC) transplantation, and yet 50% of children will succumb to leukemia relapse following this arduous therapy. 3 JMML is renowned for displaying features of a disease based on well-defined and unambiguous genetic mutations, since most children diagnosed with JMML bear nonoverlapping loss-of-function mutations in NF1 or CBL or gain-of-function mutations in NRAS, KRAS, or PTPN11. Each of these mutations yields RAS hyperactivation with a net output of excessive signaling through RAS effector pathways, including the canonical RAF-MEK-ERK and PI3K-AKT pathways. Functionally, the hallmark of hematopoietic progenitors from individuals with JMML is cytokine-independent growth in vitro and exquisite sensitivity to the growth factor granulocyte macrophage colony-stimulating factor (GM-CSF). 4 The advent of iPSC technology has provided an opportunity to generate a renewable source of patient-derived reagents that may potentially produce authentic models of JMML in vitro and in vivo for deeper molecular analysis, straightforward and efficient screening of novel pharmacologic
